Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD
- Resource Type
- Source
- Airway pharmacology and treatment.
- Subject
Moderate to severe COPD medicine.medical_specialty business.industry Internal medicine Phosphodiesterase 4 Inhibitor medicine In patient medicine.disease business Gastroenterology - Language